<DOC>
	<DOCNO>NCT00938860</DOCNO>
	<brief_summary>This study ass rate Sustained Virological Response follow anti-viral therapy Peg-Interferon plus Ribavirin patient liver transplant recurrent Hepatitis C treat Neoral tacrolimus .</brief_summary>
	<brief_title>Sustained Virological Response ( SVR ) Antiviral Treatment Liver Transplant Recipients With Recurrent Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Inclusion criterion : Liver transplantation perform least 6 month 5 year prior randomization due HCV cirrhosis , without pretransplant hepatocellular carcinoma ( HCC ) within Milan UCSF criterion Immunosuppresive regimen base tacrolimus b.i.d . ( twice daily ) least 6 month prior randomization Diagnosis HCV genotypes 1 4 infection prior transplantationconfirmed screening Indication treatment PegIFN ribavirin due histological evidence chronic HCV infection define fibrosis stage equal great 1 use IshakKnodell score system ( IK ≥1 ) liver biopsy perform screen 4 month prior randomization . Exclusion criterion : Serum creatinine &gt; 150 μmol/L ( 1.6 7 mg/dL ) eGFR &lt; 50 ml/min ( 4variable Modification Diet Renal Disease [ MDRD CockcroftGault formula ] ) Multiorgan transplant recipient Recent episode steroidtreated acute rejection ( AR ) within 3 month prior randomization , &gt; 1 episode steroidtreated AR last 6 month , number steroidresistant AR episode last 6 month include evidence chronic rejection ductopenia Evidence condition could cause graft dysfunction HCV infection Patients sign decompensated liver disease , define presence ascites , variceal bleeding , encephalopathy deteriorate hepatic synthetic function ( albumin &lt; 3.5g/dL , total direct bilirubin &gt; 1.5mg/dL , INR &gt; 1.5 ) Coinfection HIV Hepatitis B ( define HBsAgpositive ) screening Use mTOR inhibitor ( everolimus sirolimus ) 6 month prior screen Antiviral treatment HCV administer time liver transplantation Patients daily dos corticosteroids high 5 mg/day Patients fibrosing cholestatic hepatitis Patients current diagnosis malignancy , include lymphoproliferative disorder Patients platelet count &lt; 70,000/mm3 neutrophile &lt; 1,500/mm3 History HCC outside Milan criterion base radiology UCSF criterion base analysis explant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>anti-viral therapy</keyword>
</DOC>